<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196898</url>
  </required_header>
  <id_info>
    <org_study_id>1.0 / 03.02.05</org_study_id>
    <secondary_id>Grant 01 GI 0201/01 GI 0401</secondary_id>
    <nct_id>NCT00196898</nct_id>
  </id_info>
  <brief_title>Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists</brief_title>
  <official_title>A National, Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson´s Disease Treated With Dopamine Agonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Parkinson Study Group (GPS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Competence Network on Parkinson's Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Parkinson Study Group (GPS)</source>
  <brief_summary>
    <textblock>
      Fibrotic valvular heart diseases are known as rare complications of long-time therapy of&#xD;
      Parkinson's disease with ergot-derivatives including some ergot-dopamine agonists. The aim of&#xD;
      this study is to assess the incidence of valvular heart disease, which may be an ergot-drug&#xD;
      agonists side-effect or an overall complication of all dopamine agonists. Incidence,&#xD;
      prevalence and addiction of dose or intake duration are not known so far. The reversibility&#xD;
      of the changes is unknown too. To answer these questions the present study is designed as a&#xD;
      cross sectional study followed by a 2 year follow-up prospective cohort study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rare incidence of pleuropulmonary and retroperitoneal fibrosis are known complications during&#xD;
      the long-time therapy of Parkinson's disease (PD) with ergot-drug derivatives including some&#xD;
      ergot dopamine agonists. Particularly the appearance of fibrotic valvular heart disease of&#xD;
      Parkinson patients under Pergolide therapy caused an intense discussion about the safety of&#xD;
      dopamine agonists at all. Single case reports of similar heart valve changes under the&#xD;
      therapy of Bromocriptin and probably Cabergoline pointed to an effect of the whole substance&#xD;
      class of the ergot-dopamine agonists.&#xD;
&#xD;
      Cross-Sectional Study (part I):&#xD;
&#xD;
      Within this study an initial cross-sectional analysis of the prevalence of fibrotic heart&#xD;
      valvular disease will be done. Patients with Parkinson's disease with different exposition&#xD;
      status will be recruited. An transthoracal echocardiographic examination (TTE) of the heart&#xD;
      will be performed.&#xD;
&#xD;
      Exposition status:&#xD;
&#xD;
        -  patients with ergot-derived dopamine agonists&#xD;
&#xD;
        -  patients with non-ergot-derived dopamine agonists&#xD;
&#xD;
        -  After the TTE-report the study population is divided in affected (= pathological&#xD;
           TTE-report: fibrotic valvular heart diseases) and healthy persons (= non-pathological&#xD;
           TTE-report: no fibrotic valvular heart diseases). The therapy with dopamine agonist will&#xD;
           be stopped in patients with a pathological TTE-report. Instead these patients will be&#xD;
           treated with an equivalent dose of L-Dopa with or without COMT-inhibitors. The existing&#xD;
           therapy regime will remain in patients without pathological findings.&#xD;
&#xD;
      Longitudinal Section (part II and III):&#xD;
&#xD;
      The cross-sectional study (part I) is followed by a two year follow-up study.&#xD;
&#xD;
      Cohort I:&#xD;
&#xD;
        -  patients with pathological TTE-report: fibrotic valvular heart disease&#xD;
&#xD;
        -  patients without pathological TTE-report: no fibrotic valvular heart disease&#xD;
&#xD;
      Part II: Within cohort I the reversibility of fibrotic valvular heart disease will be&#xD;
      analysed with regard to the previously taken cumulative dose of dopamine agonists.&#xD;
&#xD;
      Part III: Within cohort II there will be a prospective analysis of the (cumulative) incidence&#xD;
      of fibrotic valvular heart disease in PD patients with different exposition status. If&#xD;
      fibrotic valvular heart disease occurs, a patient will be changed from cohort II to cohort I.&#xD;
&#xD;
      Primary Outcome:&#xD;
&#xD;
      Cross-sectional study (part I):&#xD;
&#xD;
        -  What is the prevalence of fibrotic valvular heart disease in PD patients under therapy&#xD;
           with ergot-derived dopamine agonists and non-ergot-derived dopamine agonists?&#xD;
&#xD;
        -  Is there an influence to the cumulative dose of dopamine agonists?&#xD;
&#xD;
      Longitudinal study (prospective cohort study):&#xD;
&#xD;
        -  (Part II) Is fibrotic valvular heart disease under therapy of ergot-derived dopamine&#xD;
           agonists and non-ergot-derived dopamine agonists reversible?&#xD;
&#xD;
        -  (Part III) What is the (cumulative) incidence of fibrotic valvular heart disease under&#xD;
           the therapy of ergot-derived dopamine agonists and non-ergot-derived dopamine agonists?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Valve Diseases</condition>
  <condition>Parkinson's Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        PD Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Diagnosis of Morbus Parkinson&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of carcinoid syndrome&#xD;
&#xD;
          -  Patients with a history of post-inflammatory (rheumatic), degenerative (calcified) or&#xD;
             ischaemic coronary heart or valvular heart disease&#xD;
&#xD;
          -  Previous medication with ergot-derived drugs (eg. Methysergide, Ergotamine) except&#xD;
             dopamine receptor agonists or anorectic drugs (eg. Fenfluramine, Dexfenfluramine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Oertel, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Marburg und Gießen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karla Eggert, Dr.</last_name>
    <phone>+49 (0)6421 2865443</phone>
    <email>eggert@med.uni-marburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolfgang M. Oertel, Prof. Dr.</last_name>
    <phone>+49 (0) 6421 866278</phone>
    <email>oertelw@med.uni-marburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg und Gießen, Neurologische Klinik</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang H. Oertel, Prof. Dr.</last_name>
      <phone>+ 49 6421- 28 66278</phone>
      <email>oertelw@med.uni-marburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Karla M. Eggert, Dr.</last_name>
      <phone>+ 49 6421- 28 65443</phone>
      <email>eggert@med.uni-marburg</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang H. Oertel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karla M Eggert, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-parkinson.de</url>
    <description>Homepage Competence Network on Parkinson's disease sponsored by the German government</description>
  </link>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <name_title>Competence Network on Parkinson´s disease, Dr. Karla Eggert</name_title>
    <organization>Competence Network on Parkinson´s disease</organization>
  </responsible_party>
  <keyword>Parkinson´s disease</keyword>
  <keyword>fibrotic valvular heart fibrosis</keyword>
  <keyword>ergot dopamine agonists</keyword>
  <keyword>non-ergot dopamine agonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

